Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Korro Bio, Inc.
Korro Bio, Inc. News
Korro Bio, Inc. Quantitative Score
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Korro Bio, Inc. Financials
Table Compare
Compare KRRO metrics with: | |||
|---|---|---|---|
Earnings & Growth | KRRO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | KRRO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | KRRO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | KRRO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Korro Bio, Inc. Income
Korro Bio, Inc. Balance Sheet
Korro Bio, Inc. Cash Flow
Korro Bio, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Korro Bio, Inc. Executives
| Name | Role |
|---|---|
| Ram Aiyar | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer & Director |
| Kemi Olugemo | Chief Medical Officer |
| Olukemi A. Olugemo | Advisor |
| Jeffrey Cerio | Senior VP, General Counsel & Corporate Secretary |
| Loic Vincent | Chief Scientific Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Ram Aiyar | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer & Director | Male | 1978 | 939.08K |
| Kemi Olugemo | Chief Medical Officer | 1977 | 649.72K | |
| Olukemi A. Olugemo | Advisor | 1976 | 649.72K | |
| Jeffrey Cerio | Senior VP, General Counsel & Corporate Secretary | Male | 615.03K | |
| Loic Vincent | Chief Scientific Officer | 592.9K |
Korro Bio, Inc. Insider Trades
| Date | 15 Dec |
| Name | Chappell Todd |
| Role | Chief Operating Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 20132 |
| Date | 15 Dec |
| Name | Vincent Loic A |
| Role | Chief Scientific Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 21715 |
| Date | 15 Dec |
| Name | Cerio Jeffrey |
| Role | General Counsel |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 41902 |
| Date | 15 Dec |
| Name | Dolan Oliver |
| Role | Senior Vice President, Finance |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 21482 |
| Date | 11 Jun |
| Name | Behbahani Ali |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 6010 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Dec | Chappell Todd | Chief Operating Officer | Acquired | A-Award | 20132 |
| 15 Dec | Vincent Loic A | Chief Scientific Officer | Acquired | A-Award | 21715 |
| 15 Dec | Cerio Jeffrey | General Counsel | Acquired | A-Award | 41902 |
| 15 Dec | Dolan Oliver | Senior Vice President, Finance | Acquired | A-Award | 21482 |
| 11 Jun | Behbahani Ali | Director, 10 percent owner | Acquired | A-Award | 6010 |